证券代码：688314 证券简称：康拓医疗 | 签单？ | | --- | | 2.无限颅内压监护仪在国内开始运作销售了没 | | 有，前景如何？ | | 答： | | 1、您好，公司口腔业务经销区域目前已覆盖西 | | 北、华中、华南等省份，在不同区域均已有签约。 | | 2、您好，目前正在推进无限颅内压监护仪产品 | | 在美国的量产工作，该产品在国内处于注册筹备阶 | | 段。无限颅内压监护仪主要用于颅脑外伤以及神经外 | | 科手术后的颅内压连续监测，该产品与公司业务具有 | | 较强的协同效应，该产品未来上市将帮助公司丰富在 | | 神外创伤和重症领域的布局，进一步奠定公司在神经 | | 外科产品高端市场的竞争力。 | | 问题二、脑膜产品已进入 FDA 认证发布审评阶 | | 段,原计划上半年完成，现在进行到哪一步了？ | | 答：尊敬的投资者：您好，公司生物再生材料人 | | --- | | FDA 工硬脑膜产品目前仍处于 审评过程中，后续进展 | | 敬请持续关注公司公告。 | | 问题三、请问三季度 Peek 胸骨带销售情况如 | | 何？推广有什么困难 | | 答：尊敬的投资者：您好，公司 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥71,474,720.87, representing a year-over-year increase of 13.30%[5] - The net profit attributable to shareholders for Q3 2023 was ¥25,166,508.55, showing a slight decrease of 2.29% compared to the same period last year[5] - The basic earnings per share for Q3 2023 was ¥0.31, down by 3.13% year-over-year[6] - Total operating revenue for the first three quarters of 2023 reached ¥206,601,313.31, an increase of 15.73% compared to ¥178,480,246.74 in the same period of 2022[18] - Net profit for Q3 2023 was ¥63,644,004.61, slightly down from ¥63,734,398.66 in Q3 2022, representing a decrease of 0.14%[20] - Earnings per share for Q3 2023 was ¥0.79, compared to ¥0.80 in Q3 2022, reflecting a decrease of 1.25%[21] - The company reported a total comprehensive income of ¥63,747,533.26 in Q3 2023, down from ¥65,449,832.96 in Q3 2022, a decrease of 2.60%[21] Research and Development - Research and development expenses totaled ¥5,458,986.56 in Q3 2023, accounting for 7.64% of operating revenue, a decrease of 0.47 percentage points from the previous year[6] - Research and development expenses for Q3 2023 were ¥13,734,653.11, up 23.56% from ¥11,122,398.10 in Q3 2022[19] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥653,557,852.75, reflecting a 2.42% increase from the end of the previous year[6] - The company's current assets totaled RMB 410,562,064.39, slightly up from RMB 404,318,862.81 in the previous year, indicating a growth of about 1.2%[15] - The company's non-current assets totaled RMB 242,995,788.36, an increase from RMB 233,816,881.07, indicating a growth of approximately 3.1%[16] - Total liabilities decreased to RMB 71,907,287.66 from RMB 87,631,814.91, representing a reduction of about 18.0%[16] - The company's accounts payable decreased significantly from RMB 19,288,782.14 to RMB 11,267,121.05, a decline of approximately 41.7%[16] - The total liabilities decreased to ¥79,297,692.68 in Q3 2023 from ¥96,462,236.78 in Q3 2022, a reduction of 17.83%[19] Cash Flow - The company reported a cash flow from operating activities of ¥64,742,464.57 year-to-date, which is a decrease of 13.60% compared to the previous year[6] - Cash inflow from operating activities for the first three quarters of 2023 totaled ¥251,458,415.59, an increase of 19.37% from ¥210,741,748.56 in the same period of 2022[22] - The net cash flow from operating activities for Q3 2023 was CNY 64,742,464.57, a decrease of 13.4% compared to CNY 74,932,246.33 in Q3 2022[24] - The net cash flow from investing activities was -CNY 148,917,105.95, worsening from -CNY 114,685,668.05 year-over-year[24] - The net cash flow from financing activities was -CNY 30,628,196.86, compared to -CNY 37,117,293.41 in the same quarter last year, indicating an improvement[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,941[12] - The largest shareholder, Hu Liren, holds 39,435,788 shares, representing 48.54% of the total shares[12] - The company reported a total of 335,290 shares held by Shenzhen Qianhai Daoming Investment Management Co., Ltd. through various accounts[13] Government Support and Taxation - The company received government subsidies amounting to ¥2,494,781.25 during the reporting period, contributing to its non-operating income[8] - Tax payments rose significantly to CNY 45,387,774.67 in Q3 2023 from CNY 22,526,765.47 in the same period last year, marking a 101.5% increase[24] Employee Compensation - The company paid CNY 51,616,821.83 in employee compensation during Q3 2023, up from CNY 44,981,069.23 in Q3 2022, representing a 14.5% increase[24] Strategic Developments - The company has not disclosed any significant new strategies or product developments during the reporting period[14]

西安康拓医疗技术股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 06 日(星期一)下午 15:00-16:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 10 月 30 日(星期一)至 11 月 03 日(星期五)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 10 月 27 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023年第三季度经营成果、财务状况，公司计划 ...

华泰联合证券有限责任公司 关于西安康拓医疗技术股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司名称：西安康拓医疗技术股份有限 | | --- | --- | | | 公司 | | 保荐代表人姓名：郑明欣 | 联系电话：010-56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科创 板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简 称"华泰联合证券"或"保荐机构"）作为西安康拓医疗技术股份有限公司（以下简称 "康拓医疗"、"公司"或"发行人"）首次公开发行股票的保荐机构，对康拓医疗进行 持续督导，并出具 2023 年半年度（以下简称"本报告期"或"报告期"）持续督导 跟踪报告： 序号 项目 持续督导工作情况 1 建立健全并有效执行持续督导工作制 度，并针对具体的持续督导工作制定 相应的工作计划。 保荐机构已制定并严格执行持续督导 工作制度，已根据公司的具体情况制 定了相应的工作计划。 2 根据中国证监会相关规定，在持续督 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-027 西安康拓医疗技术股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持股的基本情况 本次减持计划实施前，西安康拓医疗技术股份有限公司（以下简称"公司"） 董事、总经理朱海龙先生直接持有公司股份 7,966,000 股，占公司股份总数的 9.81%。 上述股东股份来源于公司首次公开发行前持有及资本公积金转增股本的股 份，已于 2022 年 5 月 18 日解除限售并上市流通。 减持计划的实施结果情况 公司于 2023 年 7 月 4 日在上海证券交易所网站（www.sse.com.cn）披露了 《西安康拓医疗技术股份有限公司股东减持股份计划公告》（公告编号： 2023-022），公司董事、总经理朱海龙先生拟通过集中竞价和大宗交易方式减持 其持有的公司股份合计不超过 300,000 股，即不超过公司股份总数的 0.37%。拟 通过集中竞价方式减持的，自本减持计划公告之日起 15 个交 ...

关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688314 证券简称：康拓医疗 公告编号：2023-026 西安康拓医疗技术股份有限公司 上述产品取得医疗器械注册证，有利于公司丰富 PEEK 材料在颌面部缺损 修复等领域的应用，延伸产品应用边际，完善业务布局，扩大公司业务规模，提 升公司持续经营能力。 三、风险提示 上述产品获批后的未来业绩受市场拓展力度及市场实际需求多重因素影响， 产品销售及利润贡献具有不确定性，尚无法预测其对公司未来业绩的具体影响。 敬请广大投资者谨慎投资、注意投资风险。 特此公告。 西安康拓医疗技术股份有限公司董事会 2023 年 8 月 18 日 1 西安康拓医疗技术股份有限公司（以下简称"公司"）于近日取得国家药品 监督管理局颁发的第三类《医疗器械注册证》，具体情况如下： | 注册人名称 | 西安康拓医疗技术股份有限公司 | | --- | --- | | 产品名称 | 聚醚醚酮颌面部植入物 | | 适用范围/预期用途 | 本产品适用于颌面部骨缺损 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 150 million, representing a 25% year-over-year growth[11]. - The company's operating revenue for the first half of 2023 was approximately CNY 135.13 million, representing a year-on-year increase of 17.10% compared to CNY 115.39 million in the same period last year[17]. - The net profit attributable to shareholders was CNY 39.18 million, a slight increase of 0.10% from CNY 39.14 million in the previous year[17]. - The gross margin for the first half of 2023 improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[11]. - The company achieved a total revenue of 6,100 million RMB, with a net profit of 309.94 million RMB, reflecting a significant increase in performance compared to the previous year[49]. - The net profit for the first half of 2023 was CNY 54,999,328.37, compared to CNY 51,067,347.09 in the first half of 2022, reflecting a growth of about 7.4%[192]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30% based on current market trends and product demand[11]. - New product development is underway, with three innovative medical devices expected to launch by Q4 2023, aimed at enhancing surgical efficiency and patient outcomes[11]. - The company is expanding its market presence, targeting an increase in distribution channels by 40% in the next year, particularly in tier-2 and tier-3 cities[11]. - The company aims to enhance its product lines in neurosurgery, oral surgery, and cardiothoracic surgery, focusing on market-driven and industrialization goals[28]. - The company is focusing on expanding its market presence through product innovation and process improvement, with a strategic plan to integrate dental implant systems and digital surgical tools[53]. Research and Development - The company has invested RMB 20 million in R&D for new technologies, focusing on biocompatible materials and advanced surgical instruments[11]. - Research and development expenses accounted for 6.12% of operating revenue, an increase of 0.91 percentage points from the previous year[18]. - The total R&D expenditure for the reporting period was ¥8,275,666.55, representing a 37.73% increase compared to ¥6,008,783.71 in the same period last year[44]. - The company has obtained a total of 13 invention patents as of the end of the reporting period, with 1 new application filed during this period[42]. - The company is focused on developing a 3D printing method for personalized PEEK cranial implants, which aims to overcome challenges in traditional mechanical processing methods[47]. Financial Position and Cash Flow - The company has maintained a strong cash position, with cash and cash equivalents totaling RMB 100 million as of June 30, 2023[11]. - The net cash flow from operating activities decreased by 30.56% to CNY 32.38 million, primarily due to the payment of deferred taxes from the previous year[19]. - Cash and cash equivalents decreased by 44.32% to ¥194,453,926.40, primarily due to the purchase of structured deposits[74]. - The company's total assets for the reporting period were significantly impacted by the changes in cash and investments[74]. - The ending cash and cash equivalents balance was RMB 194,453,926.40, a decrease from RMB 211,560,715.95 at the end of the first half of 2022[195]. Risks and Challenges - No significant risks were identified that could materially impact the company's operations during the reporting period[11]. - The company faces risks related to new product development failures and market demand changes, which could adversely affect its long-term competitiveness[65]. Regulatory and Compliance - The company has established a comprehensive quality management system, ensuring compliance with domestic quality standards and obtaining FDA and CE certifications for multiple products[56]. - The company has committed to avoiding and reducing any form of related party transactions[140]. - The company will ensure timely and truthful reporting of any changes in shareholding by its directors and senior management[103]. Shareholder Information - Major shareholders are prohibited from transferring or managing their shares during the lock-up period[96]. - The company has a commitment to not reduce shares below the initial public offering price during the lock-up period[96]. - Shareholders holding over 5% of shares express confidence in the company's business prospects and plan to hold shares long-term post-lock-up[116].

证券代码：688314 证券简称：康拓医疗 公告编号：2023-024 西安康拓医疗技术股份有限公司 2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理， ...

西安康拓医疗技术股份有限公司 独立董事关于第二届董事会第六次会议相关事项的 独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板上市规则》、《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，我们作为西安康拓医疗技术股份有限公司（以下简称"公司"） 的独立董事，认真审阅了第二届董事会第六次会议相关的会议资料和文件，基于 独立客观的立场，本着实事求是的原则，对本次会议审议的有关事项发表独立意 见如下： 一、关于募集资金存放与实际使用情况的专项报告的独立意见 经核查，我们认为：公司 2023 年半年度募集资金存放与实际使用情况符合 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》及公司《募集 资金使用管理办法》等法律法规的规定，对募集资金进行了专户存储和专项使用， 并及时履行了相关信息披露义务，募集资金具体使用情况与公司已披露情况一致， 不存在变相改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金 的情形。我们一致同意公司董事会出具的 2023 年半 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-025 西安康拓医疗技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 08 月 24 日(星期四)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 17 日(星期四)至 08 月 23 日(星期三)16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 8 月 16 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经 ...